Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study

Turner, Steve W.; Richardson, Kathryn; Burden, Annie; Thomas, Mike; Murray, Clare; Price, David
June 2015
Primary Care Respiratory Society UK;6/11/2015, p1
Academic Journal
BACKGROUND: When standard doses of inhaled corticosteroids (ICS) fail to control symptoms in children aged >4 years, guidelines recommend the addition of a long-acting β2-agonist (LABA), with other treatment options being available if symptoms persist. AIMS: To determine the proportion of initial 'step-up' episodes where LABAs were prescribed and to describe characteristics of individuals not stepped up with LABA. METHODS: Between 1999 and 2011, initial step-up episodes from ICS monotherapy were identified in children aged 5-12 years with asthma and in receipt of ICS. Data sources were the Clinical Practice Research Datalink and Optimum Patient Care Research Database. RESULTS: Initial step-up episodes were identified in 10,793 children. ICS dose was increased in 6,252 children (58%), LABA was introduced in 3,436 (32%; including 1,107 where fixed dose combination inhaler (FDC) replaced the ICS inhaler), and leukotriene receptor antagonist (LTRA) was added in 1,105 (10%). Compared with children stepped up to any LABA, others were younger and prescribed lower doses of ICS and reliever medication. ICS dose increase was more likely in obese children and LTRA prescribing was more likely in children with rhinitis and in receipt of antibiotics. Compared with FDC, step-up to separate LABA inhaler was more likely in younger, obese children who were using less oral steroids. CONCLUSIONS: One-third of initial step-up episodes in children with asthma treated with ICS are to add LABA. Different characteristics of children prescribed therapies other than LABA suggest that prescribers tailor treatment in some clinical settings.


Related Articles

  • Cost Considerations of Therapeutic Options for Children with Asthma. Chuang, Sandra; Jaffe, Adam // Pediatric Drugs;8/1/2012, Vol. 14 Issue 4, p211 

    Asthma is a prevalent health condition in children, with economic implications for the individual and their family, as well as for societies with nationalized healthcare. Pharmaceutical cost is the main driver of healthcare expenditure in asthma. Existent explicit guidelines are meant to guide...

  • Addition of Long-Acting Beta Agonists for Asthma in Children. SERVEY, JESSICA // American Family Physician;2015 Special Issue, Vol. 91, p1 

    The article discusses a study on improved measurable lung function in children with persistent asthma by adding a long-acting beta agonist (LABA) to existing treatment with an inhaled corticosteroid. Topics addressed include comparisons of results between treatment with the current...

  • Inhalent Marketed for Use in Young Children with Asthma.  // FDA Consumer;Nov/Dec2000, Vol. 34 Issue 6, p4 

    Provides information on Pulmicort Respules, an inhaled corticosteroid for young children with asthma. Details on inhaled corticosteroids; Side effects of the drug; Effect of corticosteroids on a child's growth.

  • What is the preferred treatment for a child with mild persistent asthma? Labruzzo, Brice A.; Edgerton, Lisa; Rideout, Stacy // Journal of Family Practice;Feb2007, Vol. 56 Issue 2, p137 

    The article provides information about the preferred treatment of mild persistent asthma in children. According to randomized controlled trials, low-dosed inhaled corticosteroids are preferred as therapeutics for children with mild persistent asthma, due to the superior reduction in severity and...

  • Changes in recommended treatments for mild and moderate asthma. Redding, Gregory J.; Stoloff, Stuart W. // Journal of Family Practice;Sep2004, Vol. 53 Issue 9, p692 

    This article reviews the 2002 National Asthma Education and Prevention Program (NAEPP) recommendations for the use of controlled medications for asthma, including the relative effectiveness of inhaled corticosteroids (ICSs) versus other controller medications, safety of long-term ICS use in...

  • Inhaled corticosteroids appear to have little risk of causing adverse effects on growth, bone density or cortisol levels in children with asthma.  // Drugs & Therapy Perspectives;Jul2007, Vol. 23 Issue 7, p21 

    A systematic review of studies of the long-term use of inhaled corticosteroids in children with asthma suggests that recommended doses of inhaled corticosteroids can be administered to children for the long-term management of asthma with minimal risk of clinically relevant adverse effects on...

  • Does Dose Reduction of an Inhaled Corticosteroid with the Addition of Leukotriene Antagonist is Clinical Significance in Asthma Patients? A Randomized Clinical Trial. Rajanandh, M. G.; Nageswari, A. D.; Irshad, P. P.; Ramasamy, C. // World Applied Sciences Journal;2013, Vol. 24 Issue 3, p276 

    Asthma is an inflammatory disease characterized by recurrent episodes of breathlessness and wheezing. Though inhaled corticosteroids (ICS) play a vital role in the treatment of asthma, it has commendable side effects. Reduction of ICS dose with any other drug combination may therefore be of...

  • Ten-year prescription trends of asthma medications in the management of childhood wheeze. Soh, Jian Yi; Ng, Beatrice; Tan, Zeying; Xu, Shuhui; Hing, Wee Chuan; Wu, Tuck Seng; Chan, Yiong Huak; Lee, Bee Wah // Allergy & Asthma Proceedings;Jan/Feb2014, Vol. 35 Issue 1, p1 

    Asthma is the most common chronic disorder of childhood. The aim of this study was to assess prescription trends of asthma medications to provide a measure to evaluate treatment practices and compliance with established international practice guidelines. A retrospective study of data obtained...

  • Oral Corticosteroids in Children with Wheezing. Bush, Andrew // New England Journal of Medicine;4/16/2009, Vol. 360 Issue 16, p1673 

    The article presents a response to a letter to the editor by Andrew Bush, author of an editorial discussing the article "Oral prednisolone for preschool children with acute virus-induced wheezing," by J. Panickar, M. Lakhanpaul, and PC Lambert, et al., published in a previous issue.

  • Asthma medications may be less effective in overweight children. Richards, Cassandra A.; Stott, Bob; Volansky, Rob; Wray, Charles // Infectious Diseases in Children;Apr2012, Vol. 25 Issue 4, p18 

    The article reports that a corticosteroid medication is possibly less effective in children with asthma who are overweight based on a study by Pia Hauk et al. of National Jewish Health in Denver, Colorado.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics